Sichuan Shenghe Pharmaceutical Co., Ltd., Langyi Houttuynia cordata eye drops, one of the top ten eye drop brands, is a high-tech pharmaceutical enterprise integrating drug research/development, production and pharmaceutical trade
Sichuan Shenghe Pharmaceutical Co., Ltd. is a high-tech pharmaceutical enterprise integrating drug research, development, production and pharmaceutical investment.
The company has three pharmaceutical branches and a provincial enterprise technology center. It has more than 20 production lines for small-volume injections, large-volume injections, tablets, hard capsules, granules, eye drops, mixtures, syrup, oral solutions, APIs, etc.; It produces 10 dosage forms, 240 varieties and specifications of drugs and 4 varieties and specifications of health food.
The product system has 51 patents (including 32 invention patents), 15 exclusive varieties, and 6 protected varieties of traditional Chinese medicine; Among the 151 product dosage forms, 95 were selected into the National Medical Insurance Catalogue and 39 were selected into the National Essential Medicines Catalogue. The leading products are traditional Chinese medicine injection series, ophthalmic drug series, specialized solid preparation series, anti-tumor drug series, etc., and it is one of the core enterprises in the field of traditional Chinese medicine injection in China. The professional sales and promotion network covers 33 provinces (cities) across the country, more than 500 large and medium-sized pharmaceutical business enterprises and nearly 10,000 terminal hospitals; The leading products such as Shenmai Injection, Xiangdan Injection, Danshen Injection, Houttuynia Cordata Eye Drops, Itchy Granules, and Tangmaikang Granules all rank among the top 5 in the domestic market share.
In the past decade, Shenghe Pharmaceutical has achieved sustained and rapid growth. For 10 consecutive years, it has been selected as one of the 50 key advantageous enterprises in Chengdu and 80 key advantageous enterprises in Sichuan Province; It has been selected as one of the top 10 largest pharmaceutical industry enterprises in Sichuan Province for 8 consecutive years; In 2011, it was selected as one of the top 100 pharmaceutical companies in China by the Ministry of Industry and Information Technology. The company's development strategy direction is modern Chinese medicine manufacturing and the pharmaceutical circulation and medical service industry chain extended around pharmaceuticals. In the next 5~10 years, it will mainly develop traditional Chinese medicine injections, anti-tumor drugs, and ophthalmology and endocrine specialty drugs, and become one of the major Chinese patent medicine pharmaceutical enterprises in China, and become a large-scale high-tech pharmaceutical industry group company with a high degree of specialization, integrating drug research and development, drug production, pharmaceutical circulation and medical services.
